Abivax presents first-half 2024 financial results

Abivax presents first-half 2024 financial results cash balance of eur 222m at june 30, 2024; cash runway in to q4 2025 paris, france, september 9, 2024, 10:00 p.m. cest – abivax sa (euronext paris: fr0012333284 – abvx) (“abivax” or the “company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its 2024 half-year financial results, as of june 30, 2024.
ABVX Ratings Summary
ABVX Quant Ranking